Wondering how a lab idea turns into a company? Biotech startup funding usually moves through grants, seed money, then venture rounds, each tied to scientific proof. Here is how that ladder works.
This guide sits within our wider look at the biotech industry.
| Item | Value |
|---|---|
| Average seed round (MassBio report) | $4.65 million |
| Mean Series A round (MassBio report) | nearly $80 million |
| Mean Series A round, 2023 | $63.6m |
| Mean Series A round, 2022 high | $66.4m |
| Series A share of annual biotech venture funding | just over one-third |
Figures come from BioPharma Dive via MassBio and Citeline’s In Vivo. They change with each reporting period and dataset, so check the source before you rely on them.
Why biotech startups need so much outside money
A drug or diagnostic can take years of lab work before it earns a cent. During that time the company pays scientists, rents lab space and runs expensive experiments.
Young biotech companies may depend on outside capital before they generate sales. Investors are betting on data, a team and a plan, not on revenue.
What a company needs also depends on what it builds. A tools company can sell products early, while a therapeutics company may not. Our guide to types of biotech companies shows how different the money needs can be.
The usual funding ladder
Most startups raise money in stages. Each stage is meant to fund enough work to prove the next big risk is smaller.
- Founders and friends: personal savings and small checks to get early experiments done.
- Grants: non-dilutive money from government agencies, foundations and universities.
- Angel and seed investors: early cash to build a first dataset and a team.
- Series A: the first large venture round, often used to move a lead program toward the clinic.
- Later rounds, partnerships and public markets: bigger money for human trials, manufacturing and growth.
Not every company climbs every rung. Some are sold to a larger firm early, and others stay small and focused on services or tools.
What do seed and Series A rounds look like in numbers?
Round sizes give you a feel for the gap between early and later stages. In a MassBio report covered by BioPharma Dive, the average seed round fell to $4.65 million while the mean Series A grew to nearly $80 million, as reported on the MassBio-focused article.
MassBio warned that its “biggest concern” is the “earliest startups with the riskiest science.” In plain terms, investors increasingly prefer companies that have already reduced risk.
Citeline’s In Vivo analysis shows the same scale from another angle. In 2023 the mean A round was $63.6m, just slightly behind the $66.4m high of the previous year, according to Citeline.
Series A rounds also matter for the whole market. Over the seven years Citeline reviewed, they averaged just over one-third of annual venture funding for biotechs.
How many new companies get a first big round?
Series A activity is a handy proxy for new company creation. Citeline reports a five-year high of 200 transactions in 2021, then a 19% decline to 162 in 2022.
It then reports a 40% drop from 2022 to 2023, when just under 100 startups received Series A money. The takeaway is that funding is cyclical, and a strong market for founders can turn quickly.
For a job seeker, that cycle matters. Hiring at young companies often rises and falls with the funding climate, so a startup’s runway is worth asking about in an interview.
What investors look for before writing a check
Different investors weigh different things, but several themes come up again and again. MassBio’s head of external affairs, quoted by BioPharma Dive, said founders have to prove “novelty, commercializability and confidence in leadership.”
- Science: data that is original and hard to copy.
- A path to market: a believable story of who would pay for the product and why.
- Leadership: a team that has done something like this before, or learns fast.
- Milestones: clear goals the money will reach before the next raise.
Money also shapes who the company hires. As a startup grows, it adds scientists, regulatory staff and business roles, which you can explore in our overview of biotech departments and functions.
What this means if you want to work at a startup
Funding stage tells you a lot about the job. A company that has just closed a seed round is usually small, with scientists doing several jobs at once and few formal processes.
After a large Series A, the same company tends to add specialists. You may see roles in clinical operations, quality, regulatory affairs and finance appear, and managers begin to build teams rather than do everything themselves.
Before you accept an offer, it helps to ask a few plain questions:
- When did the company last raise money, and from whom?
- What milestone is the current cash meant to reach?
- Is the next raise tied to a specific data readout?
- Are there grants or partner payments that extend the runway?
Vague replies may warrant follow-up, because a startup’s funding position can affect job security.
Why the early gap worries the industry
The widening gap between small seed rounds and very large Series A rounds creates a hard middle stretch. A company can spend its seed money before it has the data a Series A investor wants to see.
Founders respond in different ways. Some stretch a seed round by running narrower experiments, some lean harder on grants, and others partner with a university or a larger company to share costs.
This is one reason many young companies stay lean and focus on a single program. Fewer programs mean a smaller bill and a cleaner story for investors.
Non-dilutive money and partnerships
Grants and some partnership arrangements fund work without selling shares; other partnerships include equity investment. Founders often use them to produce the data that makes a later venture round possible.
A larger company may also pay a startup to develop a product together, or license a program. That brings cash and validation, though it can limit what the startup controls.
Each source has trade-offs, so most startups combine several. Grant programs, in particular, change their rules and award limits, so check the funder directly.
Frequently asked questions
What is the first money a biotech startup usually raises?
Show answer
It is often founder savings, grants or a small angel or seed investment. The aim is to produce enough early data to attract larger investors.
Is a seed round the same as a Series A?
Show answer
No. A seed round is smaller and earlier, while a Series A is the first big venture round. The MassBio figures above show the average seed at $4.65 million against a mean Series A near $80 million.
Why do investors favor less risky companies?
Show answer
Early science fails often, and rounds are costly. MassBio’s report, as covered by BioPharma Dive, flagged the earliest startups with the riskiest science as its biggest concern.
Does funding affect hiring?
Show answer
Yes. A company with recent funding can usually hire, while one near the end of its cash may cut roles. Asking about runway is reasonable when you interview.
